This process was accompanied by the release of ICD markers calreticulin (CRT) and high-mobility group box 1 (HMGB1), which significantly promoted DC maturation, CD8+ T-cell infiltration, and pro-inflammatory cytokine secretion, ultimately achieving significant tumor suppression and activating a systemic anti-tumor immune response both in vivo and in vitro. This evidence concerns the gene CALR and neoplasm.